Faeth Announces Positive Phase 2 Endometrial Cancer Results
Faeth released preliminary efficacy data from its PIKTOR trial in advanced endometrial cancer, showing an ORR of 33%. The results support progression into a Phase 3 trial given favorable safety and efficacy compared to current standards of care.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed